Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Language
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
A long-acting GLP-1 derivative...
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Permanent link
A long-acting GLP-1 derivative, NN2211: its use in the treatment of Type 2 diabetes
Bibliographic Details
Main Authors:
Matthews, DR
,
Madsbad, S
,
Schmitz, O
,
Langendorf, K
,
Jakobsen, G
Format:
Conference item
Published:
2002
Holdings
Description
Similar Items
Staff View
Similar Items
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
by: Madsbad, S, et al.
Published: (2004)
Complete Classification of (24,12) and (22,11) Self-dual Codes
by: Pless, Vera, et al.
Published: (2023)
Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist.
by: Qinghua Wang, et al.
Published: (2010-09-01)
Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
by: Chudleigh RA, et al.
Published: (2020-02-01)
Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice
by: Morieri ML, et al.
Published: (2020-11-01)